CorMedix Inc. Common Stock CRMD
HEALTHCARE · BIOTECHNOLOGYi
Market dataready · fetched 2026-11-07T02:20:06.887Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-07T00:54:28.250437716Z
FundamentalsAlpha Vantage · ready · quarter 2026-06-30 · fetched 2026-11-07T02:20:05.909451+00:00
CorMedix Inc. Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | ||||||
| 25Δ | ||||||
| 30Δ | 5.02 | 73.6% | 9.2% | |||
| 35Δ | 5.12 | 73.1% | 8.4% | |||
| 40Δ | 5.22 | 72.6% | 7.6% | |||
| 45Δ | 5.85 | 143.4% | 17.3% | 5.33 | 72.0% | 6.8% |
| 50Δ | 5.67 | 132.3% | 14.5% | 5.43 | 71.5% | 5.9% |
| 55Δ | 5.49 | 121.1% | 11.7% | 5.53 | 70.9% | 5.1% |
| 60Δ | 5.30 | 110.0% | 8.9% | |||
| 65Δ | 5.12 | 98.8% | 6.1% | |||
| 70Δ | ||||||
| 75Δ | ||||||
| 80Δ | 3.87 | 320.6% | 10.4% | |||
20Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
25Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
30Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 5.02
- IV
- 73.6%
- B/E move
- 9.2%
35Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 5.12
- IV
- 73.1%
- B/E move
- 8.4%
40Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 5.22
- IV
- 72.6%
- B/E move
- 7.6%
45Δ
- Pseudo strike
- 5.85
- IV
- 143.4%
- B/E move
- 17.3%
- Pseudo strike
- 5.33
- IV
- 72.0%
- B/E move
- 6.8%
50Δ
- Pseudo strike
- 5.67
- IV
- 132.3%
- B/E move
- 14.5%
- Pseudo strike
- 5.43
- IV
- 71.5%
- B/E move
- 5.9%
55Δ
- Pseudo strike
- 5.49
- IV
- 121.1%
- B/E move
- 11.7%
- Pseudo strike
- 5.53
- IV
- 70.9%
- B/E move
- 5.1%
60Δ
- Pseudo strike
- 5.30
- IV
- 110.0%
- B/E move
- 8.9%
- Pseudo strike
- IV
- B/E move
65Δ
- Pseudo strike
- 5.12
- IV
- 98.8%
- B/E move
- 6.1%
- Pseudo strike
- IV
- B/E move
70Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
75Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
80Δ
- Pseudo strike
- 3.87
- IV
- 320.6%
- B/E move
- 10.4%
- Pseudo strike
- IV
- B/E move
Options history
Table
| Date | IV (%) |
|---|---|
| 78.21% | |
| 73.72% | |
| 81.15% | |
| 119.67% | |
| 53.76% | |
| 49.64% | |
| 51.91% | |
| 79.72% | |
| 59.69% | |
| 65.23% | |
| 60.91% | |
| 78.83% | |
| 120.67% | |
| 68.73% | |
| 52.75% | |
| 56.08% | |
| 59.65% | |
| 53.90% | |
| 51.49% | |
| 58.77% | |
| 56.69% | |
| 74.87% | |
| 76.02% | |
| 89.77% | |
| 117.20% | |
| 77.36% | |
| 74.51% | |
| 68.67% | |
| 63.14% | |
| 72.15% | |
| 78.07% | |
| 80.06% | |
| 80.38% | |
| 77.26% | |
| 75.50% | |
| 87.02% |
Biotechnology
CRSP
CRISPR Therapeutics AG, a gene editing company, focuses on the development of gene-based transformative drugs for serious human diseases. The company is headquartered in Zug,…
More →CRVS
Corvus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. The company is…
More →CTMX
CytomX Therapeutics, Inc. is an oncology-focused biopharmaceutical company in the United States. The company is headquartered in South San Francisco, California.
More →CTNM
Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation,…
More →CYTK
Cytokinetics, Incorporated, an advanced stage biopharmaceutical company, focuses on discovering, developing and commercializing muscle activators and inhibitors as potential…
More →DBVT
DBV Technologies SA, a clinical-stage biopharmaceutical company, is dedicated to the research and development of epicutaneous immunotherapy products. The company is headquartered…
More →